A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases

Purpose: Cyclin D1 and cyclin-dependent kinases (CDK) are commonly activated in colorectal cancer. The activity of cyclin D1 can be blocked by CDK inhibitors, including p27 (CDKN1B) and p21 (CDKN1A, which is induced by p53). However, prognostic significance of tumoral cyclin D1 remains uncertain, and no previous study has considered potential confounding effect of p53, p21, p27, and related molecular events [microsatellite instability (MSI), CpG island methylator phenotype, and LINE-1 hypomethylation]. Experimental Design: Among 602 colon cancer patients (stage I-IV) in two prospective cohort studies, cyclin D1 overexpression was detected in 330 (55%) tumors by immunohistochemistry. Cox proportional hazard models computed hazard ratios (HR) of colon cancer–specific and overall mortalities, adjusted for patient characteristics and tumoral molecular features, including p53, p21, p27, cyclooxygenase-2, fatty acid synthase, LINE-1 methylation, CpG island methylator phenotype, MSI, BMI, KRAS, and BRAF. Results: Cyclin D1 overexpression was associated with a low cancer-specific mortality in Kaplan-Meier analysis (P = 0.006), and in both univariate Cox regression [unadjusted HR, 0.64; 95% confidence interval (CI), 0.47-0.88; P = 0.0063] and multivariate analyses (adjusted HR, 0.57; 95% CI, 0.39-0.84; P = 0.0048). Similar findings were observed for an overall mortality (adjusted HR, 0.74; 95% CI, 0.57-0.98; P = 0.036). Notably, the effect of cyclin D1 on survival might differ by MSI status (Pinteraction = 0.008). Compared with tumors that were both cyclin D1–negative and MSI-low/microsatellite stable, the presence of either cyclin D1 or MSI-high or both seemed to confer better clinical outcome (adjusted HR point estimates, 0.10-0.65). Conclusions: Cyclin D1 overexpression is associated with longer survival in colon cancer.

[1]  M. Loda,et al.  CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. , 2006, The Journal of molecular diagnostics : JMD.

[2]  S. Ogino,et al.  LINE‐1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer , 2008, International journal of cancer.

[3]  Nandita Ghosh,et al.  Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma , 2001, Diseases of the colon and rectum.

[4]  Shuji Ogino,et al.  Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer , 2005, Clinical Cancer Research.

[5]  S. Theocharis,et al.  Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer , 2006, World journal of surgical oncology.

[6]  S. McClue,et al.  Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents , 2008, Clinical Cancer Research.

[7]  G. Pasz-Walczak,et al.  P21 (WAF1) expression in colorectal cancer: correlation with P53 and cyclin D1 expression, clinicopathological parameters and prognosis. , 2001, Pathology, research and practice.

[8]  G. Landberg,et al.  Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. , 1998, European journal of cancer.

[9]  M. Loda,et al.  Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component , 2006, Modern Pathology.

[10]  L. Terracciano,et al.  RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis , 2008, Clinical Cancer Research.

[11]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[12]  J. Alao,et al.  Molecular Cancer BioMed Central Review The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention , 2007 .

[13]  C. Albanese,et al.  The cyclin D 1 gene is a target of the b-catenin y LEF-1 pathway , 1999 .

[14]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[15]  M. Loda,et al.  Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. , 2007, The Journal of molecular diagnostics : JMD.

[16]  H. McLeod,et al.  Analysis of key cell‐cycle checkpoint proteins in colorectal tumours , 2002, The Journal of pathology.

[17]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[18]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[19]  A. Margeli,et al.  Expression of Peroxisome Proliferator-Activated Receptor-γ in Colon Cancer: Correlation with Histopathological Parameters, Cell Cycle-Related Molecules, and Patients’ Survival , 2007, Digestive Diseases and Sciences.

[20]  Shuji Ogino,et al.  Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. , 2006, The Journal of molecular diagnostics : JMD.

[21]  L. Terracciano,et al.  Local Recurrence in Mismatch Repair–Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes , 2008, Clinical Cancer Research.

[22]  W. Weichert,et al.  Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo , 2008, Clinical Cancer Research.

[23]  Shuji Ogino,et al.  A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. , 2008, Journal of the National Cancer Institute.

[24]  A. Bahnassy,et al.  Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients , 2004, BMC gastroenterology.

[25]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Schmid,et al.  Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations , 2007, Virchows Archiv.

[27]  Y. Collan,et al.  The Significance of Tumor Markers for Proliferation and Apoptosis in Predicting Survival in Colorectal Cancer , 2005, Diseases of the colon and rectum.

[28]  Jeffrey S. Morris,et al.  Epigenetic-Genetic Interactions in the APC/WNT, RAS/RAF, and P53 Pathways in Colorectal Carcinoma , 2008, Clinical Cancer Research.

[29]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Chan,et al.  Consistent Immunostaining for Cyclin D1 Can Be Achieved on a Routine Basis Using a Newly Available Rabbit Monoclonal Antibody , 2004, The American journal of surgical pathology.

[31]  M. Loda,et al.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.

[32]  A. Fryer,et al.  Subcellular localisation of cyclin D1 protein in colorectal tumours is associated with p21WAF1/CIP1 expression and correlates with patient survival , 2001 .

[33]  S. Curran,et al.  Profiling markers of prognosis in colorectal cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Francis Seow-Choen,et al.  A survival–stratification model of human colorectal carcinomas with β‐catenin and p27kip1 , 2002, Cancer.

[35]  D. Notterman,et al.  CpG Island Methylator Phenotype Associates with Low-Degree Chromosomal Abnormalities in Colorectal Cancer , 2008, Clinical Cancer Research.

[36]  J. Nesland,et al.  Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas , 2000, Virchows Archiv.

[37]  K. Maeda,et al.  Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma , 1997, International journal of cancer.

[38]  M. Yamakawa,et al.  Expression of cell cycle markers in colorectal carcinoma: Superiority of cyclin A as an indicator of poor prognosis , 1999, International journal of cancer.

[39]  J. Nesland,et al.  Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome , 2005, Journal of Clinical Pathology.

[40]  M. Loda,et al.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. , 2005, The Journal of molecular diagnostics : JMD.

[41]  B. Iacopetta,et al.  Tumor-Infiltrating Lymphocytes and Perforation in Colon Cancer Predict Positive Response to 5-Fluorouracil Chemotherapy , 2008, Clinical Cancer Research.

[42]  M. Loda,et al.  Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP , 2007, Modern Pathology.

[43]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[44]  M. Loda,et al.  Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. , 2006, Neoplasia.

[45]  E. Schuuring,et al.  Cortactin expression predicts poor survival in laryngeal carcinoma , 2008, British Journal of Cancer.

[46]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[47]  J. Nesland,et al.  Expression of non‐membranous β‐catenin and γ‐catenin, c‐Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[48]  S. Ogino,et al.  Molecular classification and correlates in colorectal cancer. , 2008, The Journal of molecular diagnostics : JMD.

[49]  D. Sargent,et al.  Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer , 2008, Clinical Cancer Research.

[50]  I. Petersen,et al.  Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. , 2005, Neoplasia.

[51]  H. Hibshoosh,et al.  Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. , 1996, Gastroenterology.

[52]  S. Ogino,et al.  Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype , 2008, Histopathology.